Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai said Aug. 24 that it had obtained U.S. FDA approval for an oral capsule formulation of Aloxi (palonosetron) for preventing chemotherapy-induced nausea and voting, broadening the company's reach into the CINV market

You may also be interested in...

Eisai Wins U.S. FDA Post-Operative Indication For Antiemetic Aloxi

U.S. FDA has approved a new indication for Japan-based Eisai's Aloxi (palonosetron hydrochloride) for post-operative nausea and vomiting in the first 24 hours after surgery. The drug maker announced approval of the expanded indication March 3 for the drug it obtained through the acquisition of MGI Pharma earlier this year (PharmAsia News, Jan. 24, 2008).

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts